Drugs / norUDCA
norUDCA
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01755507 | Dec 2012 → Oct 2015 | primary sclerosing cholangitis | Dr. Falk Pharma GmbH | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | norUDCA | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01755507 ↗ |
| Known as | 24-norursodeoxycholic acid | “24-norursodeoxycholic acid (norUDCA) is a side chain-shortened C23 homologue of UDCA and has shown potent anti-cholestatic, anti-inflammatory and anti-fibrotic properties in a...” PMID 28529147 ↗ May 2017 |
| Known as | norursodeoxycholic acid | “In this phase II clinical study in PSC patients, a side chain-shortened derivative of ursodeoxycholic acid, norursodeoxycholic acid (norUDCA), significantly reduced serum...” PMID 28529147 ↗ May 2017 |
| Route | Oral | “oral treatment with either 500 mg/d, 1000 mg/d or 1500 mg/d norursodeoxycholic acid capsules” NCT01755507 ↗ |